The Clinical Utility of Ki67 in Breast Cancer
Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.
Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.
In his presentation at the 12th International Congress on the Future of Breast Cancer from July 18-20, 2013, in Huntington Beach, CA, Nielsen discussed the clinical utility of the Ki67 protein in breast cancer.
Clinical Pearls
Ki67 is a convenient immunohistochemical tool for measuring proliferation, which is a critical factor in breast cancer, as well as in other cancers. The nature of the Ki67 protein, with its repeated element, is beneficial for an antigen antibody interaction. This produces the best, cheapest, and most widely available immunohistochemistry to measure proliferation on standard paraffin biopsy specimens.
- Ki67 is a convenient immunohistochemical tool for measuring proliferation
- The nature of the Ki67 protein is very good for an antigen antibody interaction
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
